Markus Jerling

Member of TFS Scientific Advisory Board

Markus Jerling is a licensed Medical Doctor with board certification in Clinical Pharmacology. He holds a PhD degree from the Karolinska Institute in pharmacokinetic-pharmacodynamic modeling. Markus initially practiced medicine for several years in the areas of anesthesiology, pulmonary medicine and psychiatry, and joined the pharmaceutical industry in 1995 as head of Clinical Pharmacology at Astra Arcus that developed drugs for CNS related disorders. After a period as director of clinical drug safety at Pharmacia in Sweden he moved to CV Therapeutics in Palo Alto, California, to take on a position as Vice President of Clinical Research. The responsibility included setting up a Clinical Pharmacology function and the medical leadership for a pivotal phase III program. During this time he had frequent contacts with the FDA and compiled Clinical Pharmacology sections for two NDAs that were approved by the FDA and EMEA. After moving back to Europe Markus was appointed head of Clinical Pharmacology at Novo Nordisk in Denmark with projects in diabetes and bleeding disorders. He thereafter set up his own consultancy service in clinical drug development and in 2007 joined NeuroNova AB as Chief Medical Officer.

Markus has been extensively involved in the design, execution and evaluation of in particular early clinical trials in several therapeutic areas. His research interests include the dose dependency of drug effects, drug development strategies including the use of biomarkers, and safety evaluation of drug candidates. He is member of the American College of Clinical Pharmacology and the American Society for Clinical Pharmacology and Therapeutics, and referee for several scientific journals in the area of Clinical Pharmacology.